Posted by Michael Wonder on 30 May 2017
FDA approves first generic Strattera for the treatment of ADHD
30 May 2017 - The U.S. FDA today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder in paediatric and adult patients.
Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited today gained approval to market atomoxetine in multiple strengths.
"Today’s approvals mark an important step forward in bringing consumers additional treatments that have met the FDA’s rigorous standards," said Kathleen Uhl, M.D., director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. "Quickly bringing generics to market so patients have more options to treat their conditions is a top priority for the FDA."
